Clinical Trial

The Role of Acetazolamide in Mitigating Inflammation and Innate Immune Activation at High Altitude

Active, Not Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 8, 2026 (before its estimated June 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
High altitude travel can lead to inflammation in the body and activation of innate immune cells. The investigators' prior research demonstrates that 1 to 3 days at 3800 m elevation leads to increased expression of genes in blood cells that code for proteins that signal cell damage (damage associated molecular patterns (DAMPs)), cell receptors involved in innate immune responses, as well as increases in monocyte and neutrophil cells which promote inflammation. This study will investigate the potential mechanisms underlying these effects using the drug Acetazolamide, a carbonic anhydrase inhibitor which is known to reduce symptoms of Acute Mountain Sickness.
Trial Details
NCT Number NCT07517068
Lead Sponsor University of California, Riverside
Conditions Hypoxemia, Acute Mountain Sickness (AMS), Inflammation, Immune Response
Enrollment 19 participants
Start Date 2025-09-17
Primary Completion 2026-06-15 (estimated)
Study Completion 2026-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-04-08